regenHU is an innovative biomedical company located in Switzerland, which produces 3D bioprinters. AMI and regenHU have teamed up to develop and industrialize a new cell culture platform technology for in vitro lung models that offers a true high throughput alternative to animal testing and opens up new opportunities for its customers. This had led to a number of other AMI projects including: 

Bioprinting of tissue/spheroids

This project focuses on the development of a reproducible human omentum model using three-dimensional (3D) bioprinting technology, which allows spatially controlled deposition of cells and biomaterials in an automated process. We aim to mimic the defined structure of the human omentum and evaluate its capacity to simulate the in vivo condition both in healthy and diseased states. Additionally,visualization and characterization to investigate adhesion and migration property of cancer cells into this 3D human omentum tissue is envisaged.

3D tissue models to assess hazards (lung/intestine/skin)

Understanding the effects of novel nanomaterials on biological systems is a critical precursor to their further application. 2D cell monocultures are widely used in safety assessment, however, they do not represent the complex biological processes that occur within the human body. Innovative and effective in vitro cell models can more reliably predict potential human health from novel nanomaterials. This project focuses on the establishment of complex 3D cell culture models of our main physiological barriers to the outside world such as the lung, the intestine and the skin.